OBJECTIVE: To assess whether the WHO staging classification for HIV provides prognostically valuable and applicable information in rural Uganda. PATIENTS AND STUDY DESIGN: Data were obtained from a population-based cohort of 232 HIV-infected individuals. METHODS: Clinical information was obtained using a detailed questionnaire and ascertained by physical examination. Participants were seen routinely every 3 months and when they were sick. A computer algorithm based on clinical history, examination and laboratory findings was used to stage HIV-positive participants at each routine visit. Kaplan-Meier survival estimates and the Cox proportional hazard model were used to assess the prognostic strength of the clinical and laboratory categories of the system. RESULTS: An attendance rate of 81% and 799 person-years of follow-up were achieved. Survival probability estimates at 6 years from being seen in clinical stages 1, 2, 3 and 4 were 63, 46, 24 and 6% respectively. When staging was revised to incorporate lymphocyte categories, the survival probabilities were 73, 62, 39 and 6% respectively. Unexplained prolonged fever and severe bacterial infection had survival probabilities closer to stage 2 conditions, mucocutaneous herpes simplex virus infection for more than 1 month and crytosporidiosis with diarrhoea for more than 1 month closer to stage 3 and oral candidiasis closer to stage 4 conditions. CONCLUSIONS: Even without the laboratory markers, the clinical category of the WHO staging system is useful for predicting survival in individuals with HIV disease. This is important for areas with limited access to laboratory markers. A simple rearrangement of a few clinical conditions could improve the prognostic significance of the WHO system.
OBJECTIVE: To assess whether the WHO staging classification for HIV provides prognostically valuable and applicable information in rural Uganda. PATIENTS AND STUDY DESIGN: Data were obtained from a population-based cohort of 232 HIV-infected individuals. METHODS: Clinical information was obtained using a detailed questionnaire and ascertained by physical examination. Participants were seen routinely every 3 months and when they were sick. A computer algorithm based on clinical history, examination and laboratory findings was used to stage HIV-positive participants at each routine visit. Kaplan-Meier survival estimates and the Cox proportional hazard model were used to assess the prognostic strength of the clinical and laboratory categories of the system. RESULTS: An attendance rate of 81% and 799 person-years of follow-up were achieved. Survival probability estimates at 6 years from being seen in clinical stages 1, 2, 3 and 4 were 63, 46, 24 and 6% respectively. When staging was revised to incorporate lymphocyte categories, the survival probabilities were 73, 62, 39 and 6% respectively. Unexplained prolonged fever and severe bacterial infection had survival probabilities closer to stage 2 conditions, mucocutaneous herpes simplex virus infection for more than 1 month and crytosporidiosis with diarrhoea for more than 1 month closer to stage 3 and oral candidiasis closer to stage 4 conditions. CONCLUSIONS: Even without the laboratory markers, the clinical category of the WHO staging system is useful for predicting survival in individuals with HIV disease. This is important for areas with limited access to laboratory markers. A simple rearrangement of a few clinical conditions could improve the prognostic significance of the WHO system.
Authors: Philip J Peters; Isaac Zulu; Nzali G Kancheya; Shabir Lakhi; Elwyn Chomba; Cheswa Vwalika; Dhong-Jin Kim; Ilene Brill; Jareen Meinzen-Derr; Amanda Tichacek; Susan A Allen Journal: AIDS Res Hum Retroviruses Date: 2008-07 Impact factor: 2.205
Authors: Isaac M Kigozi; Loren M Dobkin; Jeffrey N Martin; Elvin H Geng; Winnie Muyindike; Nneka I Emenyonu; David R Bangsberg; Judith A Hahn Journal: J Acquir Immune Defic Syndr Date: 2009-10-01 Impact factor: 3.731
Authors: Annabelle J Gourlay; Carla van Tienen; Sangeeta S Dave; Tim Vincent; Sarah L Rowland-Jones; Judith R Glynn; Hilton C Whittle; Maarten F Schim van der Loeff Journal: Int J Infect Dis Date: 2012-03-02 Impact factor: 3.623
Authors: Chigomezgo Munthali; Miriam Taegtmeyer; Paul G Garner; David G Lalloo; S Bertel Squire; Elizabeth L Corbett; Nathan Ford; Peter MacPherson Journal: J Int AIDS Soc Date: 2014-06-12 Impact factor: 5.396
Authors: John Rubaihayo; Nazarius M Tumwesigye; Joseph Konde-Lule; Henry Wamani; Edith Nakku-Joloba; Fredrick Makumbi Journal: BMC Res Notes Date: 2016-12-07
Authors: Raimi Ewetola; Gulzar H Shah; Lievain Maluantesa; Gina Etheredge; Kristie Waterfield; Astrid Mulenga; Apolinaire Kilundu Journal: Int J Environ Res Public Health Date: 2021-05-17 Impact factor: 3.390
Authors: Peter Macpherson; David G Lalloo; Deus Thindwa; Emily L Webb; S Bertel Squire; Geoffrey A Chipungu; Nicola Desmond; Simon D Makombe; Miriam Taegtmeyer; Augustine T Choko; Elizabeth L Corbett Journal: J Acquir Immune Defic Syndr Date: 2014-02-01 Impact factor: 3.731